

Prior Authorization Criteria <u>Compounds</u>

Requests for compounds may require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

For requests for Compounds, all of the following criteria must be met:

- Documentation by the prescribing physician must include:
 - The indication the medication is being requested to treat
 - Any comparable commercially available preparations of the active ingredient or that contain similar active ingredients that the member has tried and/or failed and why they cannot take these medications
 - The clinical rationale for using a compounded medication versus an FDA approved product
 - Any published or clinical evidence that this compounded prescription is clinically superior to FDA approved existing therapies
- The physician or the pharmacy must document all ingredients that will be used to compound the prescription
- Each of the active ingredients in the compound must be used for an indication that is FDA approved or compendia supported
- Must meet at least 1 of the following:
 - There is a current supply shortage of the commercial product
 - The patient has a medical need for a dosage form or strength that is not commercially available
 - The patient had a trial and intolerance or contraindication to the commercially available product
 - The commercially available product has been discontinued by the manufacturer for reasons other than lack of safety or effectiveness
- If there are FDA-approved therapies or other standard therapies for the medical condition being treated, such therapies must have been tried and failed or been contraindicated for the patient. (Medication usage must be documented in patient's medical records)
- Prior authorization criteria will apply to all compounded products that exceed a cost threshold of one hundred and fifty dollars (\$150) per claim
- Initial Duration of Approval: 6 months
- Reauthorization criteria
 - Requires documentation demonstrating improvement in condition and tolerance to therapy
 - If previously approved due to shortage or discontinuation of the commercial product, a commercial product must still be unattainable at time of reauthorization

Reauthorization Duration of Approval: 6 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.



When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.



Updated: 07/2023 PARP Approved: 08/2023

		POUNDS PRIZATION FORM		
Please complete and fax all requeste			laboratory tes	t results, or chart documentation
as applica	ble to Highmark Wholecare	Pharmacy Services. F	AX: (888) 245	5-2049
If needed, you may call to speak t			800) 392-1147	Mon – Fri 8:30am to 5:00pm
	PROVIDER 1	INFORMATION	1.151	
Requesting Provider:	Provider NPI: Office Contact:			
Provider Specialty: State license #:	Office Confact: Office NPI:			
Office Address:	Office Phone:			
Office Address.	Office Fax:			
	MEMBER I	NFORMATION	4	
Member Name: DOB:				
Member ID:	Member weight: Height:			
	REQUESTED DR	UG INFORMATIO	N	
Medication:	Strength:	Strength:		
Directions:	Quantity: Refills:			
Ingredients (attach a separate list if				
	equested medication?			
Is the member currently receiving re-		Date Medication Initiated:		
This we direction will be hilled.		nformation		
This medication will be billed:	1 7 =	ically, JCODE: per's home		
		vice Information		
Name:		NPI:		
Address:	Phone:			
	MEDICAL HISTORY (Complete for ALL ro	equests)	
Diagnosis:		ICD Code:		
Provide clinical rationale for using a	a compounded prescription ov	ver an FDA-approved	product:	
What has maximuly have triad? Li	st all below.	Non abormooo	la gia thangar	
What has previously been tried? Li		s 🔲 Non-pharmaco	2	
				erapy failed, was discontinued,
Medication/Therapy Name	Dose and/or Frequency	Dates of Therapy		aindicated, or unattainable
		ORIZATION		
Is the commercial product currently	8		Yes I	No
Has the member experienced an imp		Yes No		
SU	PPORTING INFORMATI	ON or CLINICAL R	ATIONALE	
Prescribing Provid	lor Signoturo		Da	
Frescribing Provid			Da	
L				